Neutralizing and enhancing monoclonal antibodies in SARS-CoV-2 convalescent patients: lessons from early variant infection and impact on shaping emerging variants.

"Disclosure statement No potential conflict of interest was reported by the author(s)."

"Author contributions statement: F.C. and P.M. planned, coordinated, obtained funding for the study, and wrote first draft of manuscript. F.C., F.T., C.B., J.J.P., M.A., S.M., M.A. carried out experiments. F.C., J.-J.P., M.A. performed the generation and the screening of immortalized B cell clones. S.M. and M.A. carried out plates of infected cells. F.T., C.B and XdL performed and analyzed the neutralization assays. T.F. recruited participants. F.C. and P.M. wrote the manuscript with inputs from all co-authors. All authors commented on the manuscript draft and agreed with its submission."

"Samples were collected from individuals who had recovered from SARS-CoV-2 infection, vaccinated or not. The study protocols were approved by the institutional review board for ethics (Ethics Committee of the Hospitals of Lyon for the Protection of People; IDRCB 2020-A01038-31). Prior to participating in the study, all participants provided written informed consent. The study is registered on ClinicalTrials.gov (NCT04354766). Trial registration: ClinicalTrials.gov identifier: NCT04354766 Ethical approval information: Samples were obtained from SARS-CoV-2 recovered and vaccinated individuals under study protocols approved by institutional review board for ethics (Ethics Committee of the Hospitals of Lyon for the protection of people; IDRCB 2020-A01038-31). All participants provided written informed consent before their participation to the study. The study is registered on ClinicalTrials.gov (NCT04354766)."